• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于预测 III 期 NSCLC 两种混合计划方法的物理和 EQD 计划参数的回归模型。

Regression models for predicting physical and EQD plan parameters of two methods of hybrid planning for stage III NSCLC.

机构信息

Institute of Modern Physics, Fudan University, Shanghai, China.

Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.

出版信息

Radiat Oncol. 2021 Jun 27;16(1):119. doi: 10.1186/s13014-021-01848-9.

DOI:10.1186/s13014-021-01848-9
PMID:34176503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8237456/
Abstract

BACKGROUND/PURPOSE: To establish regression models of physical and equivalent dose in 2 Gy per fraction (EQD) plan parameters of two kinds of hybrid planning for stage III NSCLC.

METHODS

Two kinds of hybrid plans named conventional fraction radiotherapy & stereotactic body radiotherapy (C&S) and conventional fraction radiotherapy & simultaneous integrated boost (C&SIB) were retrospectively made for 20 patients with stage III NSCLC. Prescription dose of C&S plans was 2 Gy × 30f for planning target volume of lymph node (PTV) and 12.5 Gy × 4f for planning target volume of primary tumor (PTV), while prescription dose of C&SIB plans was 2 Gy × 26f for PTV and sequential 2 Gy × 4f for PTV combined with 12.5 Gy × 4f for PTV. Regression models of physical and EQD plan parameters were established based on anatomical geometry features for two kinds of hybrid plans. The features were mainly characterized by volume ratio, min distance and overlapping slices thickness of two structures. The possibilities of regression models of EQD plan parameters were verified by spearman's correlation coefficients between physical and EQD plan parameters, and the influence on the consistence of fitting goodness between physical and EQD models was investigated by the correlations between physical and EQD plan parameters. Finally, physical and EQD models predictions were compared with plan parameters for two new patients.

RESULTS

Physical and EQD plan parameters of PTV CI have shown strong positive correlations with PTV volume and min distance, and strong negative correlations with PTV volume for two kinds of hybrid plans. PTV CI is not only correlated with above three geometry features, but also negatively correlated with overlapping slices thickness. When neck lymph node metastasis was excluded from PTV volume, physical and EQD total lung V showed a high linear correlation with corrected volume ratio Meanwhile, physical total lung mean dose (MLD) had a high linear correlation with corrected volume ratio, while EQD total lung MLD was not only affected by corrected volume ratio but also volume ratio Heart D, D and mean dose (MHD) would be more susceptible to overlapping structure. Min distance may be an important feature for predicting EQD esophageal max dose for hybrid plans. It's feasible for regression models of EQD plan parameters, and the consistence of the fitting goodness of physical and EQD models had a positive correlation with spearman's correlation coefficients between physical and EQD plan parameters. For total lung V, ipsilateral lung V, and ipsilateral lung MLD, the models could predict that C&SIB plans were higher than C&S plans for two new patients.

CONCLUSION

The regression models of physical and EQD plan parameters were established with at least moderate fitting goodness in this work, and the models have a potential to predict physical and EQD plan parameters for two kinds of hybrid planning.

摘要

背景/目的:为了建立两种 III 期 NSCLC 混合计划的 2Gy 分次(EQD)计划参数的物理和等效剂量的回归模型。

方法

回顾性地为 20 例 III 期 NSCLC 患者制作了两种混合计划,分别为常规分次放疗与立体定向体部放疗(C&S)和常规分次放疗与同期加量放疗(C&SIB)。C&S 计划的处方剂量为淋巴结计划靶区(PTV)的 2Gy×30f 和原发肿瘤计划靶区(PTV)的 12.5Gy×4f,而 C&SIB 计划的处方剂量为 PTV 的 2Gy×26f 和 PTV 联合 12.5Gy×4f 的序贯 2Gy×4f。基于两种混合计划的解剖几何特征,建立了物理和 EQD 计划参数的回归模型。这些特征主要由两个结构的体积比、最小距离和重叠切片厚度来描述。通过物理和 EQD 计划参数之间的 Spearman 相关系数验证了 EQD 计划参数回归模型的可能性,并通过物理和 EQD 计划参数之间的相关性研究了对物理和 EQD 模型拟合优度一致性的影响。最后,将物理和 EQD 模型的预测值与两个新患者的计划参数进行了比较。

结果

两种混合计划的 PTV CI 的物理和 EQD 计划参数与 PTV 体积和最小距离呈强正相关,与 PTV 体积呈强负相关。PTV CI 不仅与上述三个几何特征相关,还与重叠切片厚度呈负相关。当排除颈部淋巴结转移时,物理和 EQD 全肺 V 与校正体积比呈高度线性相关。同时,物理全肺平均剂量(MLD)与校正体积比呈高度线性相关,而 EQD 全肺 MLD 不仅受校正体积比影响,还受体积比心脏 D、D 和平均剂量(MHD)的影响。重叠结构更敏感。最小距离可能是预测混合计划 EQD 食管最大剂量的一个重要特征。EQD 计划参数的回归模型是可行的,物理和 EQD 计划参数之间的 Spearman 相关系数与物理和 EQD 模型拟合优度的一致性呈正相关。对于全肺 V、同侧肺 V 和同侧肺 MLD,模型可以预测对于两个新患者,C&SIB 计划高于 C&S 计划。

结论

本研究中建立了至少具有中等拟合优度的物理和 EQD 计划参数回归模型,该模型有望预测两种混合计划的物理和 EQD 计划参数。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/84634b0dcd57/13014_2021_1848_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/43c6d6c1e02d/13014_2021_1848_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/89f5e233d994/13014_2021_1848_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/b4c4e5185201/13014_2021_1848_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/29af623e17c1/13014_2021_1848_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/ea5a9d167732/13014_2021_1848_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/dbf76c35b6d8/13014_2021_1848_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/84634b0dcd57/13014_2021_1848_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/43c6d6c1e02d/13014_2021_1848_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/89f5e233d994/13014_2021_1848_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/b4c4e5185201/13014_2021_1848_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/29af623e17c1/13014_2021_1848_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/ea5a9d167732/13014_2021_1848_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/dbf76c35b6d8/13014_2021_1848_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9d9/8237456/84634b0dcd57/13014_2021_1848_Fig7_HTML.jpg

相似文献

1
Regression models for predicting physical and EQD plan parameters of two methods of hybrid planning for stage III NSCLC.用于预测 III 期 NSCLC 两种混合计划方法的物理和 EQD 计划参数的回归模型。
Radiat Oncol. 2021 Jun 27;16(1):119. doi: 10.1186/s13014-021-01848-9.
2
Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC.基于体素的 BED 校正剂量学和 2 种 III 期非小细胞肺癌混合放疗计划方法的放射生物学评估。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221107966. doi: 10.1177/15330338221107966.
3
Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy.对于采用 4D-CT 强度调制放射治疗的局部晚期非小细胞肺癌,是否需要临床靶区。
BMC Cancer. 2024 Sep 27;24(1):1198. doi: 10.1186/s12885-024-12979-z.
4
Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study.同步整合推量强度调控放射治疗与常规强度调控放射治疗局部晚期非小细胞肺癌的疗效与安全性比较:一项回顾性研究。
Radiat Oncol. 2019 Jun 13;14(1):106. doi: 10.1186/s13014-019-1259-3.
5
Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.评估蒙特卡罗算法在接受立体定向体部放射治疗的周围型肺癌患者中符合 RTOG 0915 剂量学标准的应用。
J Appl Clin Med Phys. 2016 May 8;17(3):277-293. doi: 10.1120/jacmp.v17i3.6077.
6
Fully automated VMAT treatment planning for advanced-stage NSCLC patients.针对晚期非小细胞肺癌患者的全自动容积调强放疗治疗计划
Strahlenther Onkol. 2017 May;193(5):402-409. doi: 10.1007/s00066-017-1121-1. Epub 2017 Mar 17.
7
Accumulation of the delivered dose based on cone-beam CT and deformable image registration for non-small cell lung cancer treated with hypofractionated radiotherapy.基于锥形束 CT 和形变图像配准的递增量在非小细胞肺癌的低分割放射治疗中的应用。
BMC Cancer. 2020 Nov 16;20(1):1112. doi: 10.1186/s12885-020-07617-3.
8
Dose escalation for locally advanced lung cancer using adaptive radiation therapy with simultaneous integrated volume-adapted boost.使用自适应放疗和同步整体容积自适应推量进行局部晚期肺癌的剂量递增。
Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):414-9. doi: 10.1016/j.ijrobp.2012.12.027. Epub 2013 Mar 21.
9
Evaluation of adaptive treatment planning for patients with non-small cell lung cancer.非小细胞肺癌患者适应性治疗计划的评估
Phys Med Biol. 2017 Jun 7;62(11):4346-4360. doi: 10.1088/1361-6560/aa586f. Epub 2017 Jan 10.
10
SBRT combined with concurrent chemoradiation in stage III NSCLC: Feasibility study of the phase I Hybrid trial.SBRT 联合 III 期 NSCLC 同期放化疗:I 期 Hybrid 试验的可行性研究。
Radiother Oncol. 2020 Jan;142:224-229. doi: 10.1016/j.radonc.2019.07.015. Epub 2019 Aug 17.

引用本文的文献

1
Definition of a framework for volumetric modulated arc therapy plan quality assessment with integration of dose-, complexity-, and robustness metrics.容积调强弧形治疗计划质量评估框架的定义,整合剂量、复杂性和稳健性指标。
Phys Imaging Radiat Oncol. 2024 Nov 29;32:100685. doi: 10.1016/j.phro.2024.100685. eCollection 2024 Oct.
2
Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC.基于体素的 BED 校正剂量学和 2 种 III 期非小细胞肺癌混合放疗计划方法的放射生物学评估。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221107966. doi: 10.1177/15330338221107966.
3

本文引用的文献

1
Effect of lung volume on helical radiotherapy in esophageal cancer: are there predictive factors to achieve acceptable lung doses?肺容积对食管癌螺旋放疗的影响:是否存在可预测达到可接受肺剂量的因素?
Strahlenther Onkol. 2020 Sep;196(9):805-812. doi: 10.1007/s00066-020-01581-4. Epub 2020 Jan 24.
2
SBRT combined with concurrent chemoradiation in stage III NSCLC: Feasibility study of the phase I Hybrid trial.SBRT 联合 III 期 NSCLC 同期放化疗:I 期 Hybrid 试验的可行性研究。
Radiother Oncol. 2020 Jan;142:224-229. doi: 10.1016/j.radonc.2019.07.015. Epub 2019 Aug 17.
3
Multi-Institutional Validation of a Knowledge-Based Planning Model for Patients Enrolled in RTOG 0617: Implications for Plan Quality Controls in Cooperative Group Trials.
Investigation of Predictors to Achieve Acceptable Lung Dose in T-Shaped Upper and Middle Esophageal Cancer With IMRT and VMAT.
调强放疗和容积旋转调强放疗用于T形上中段食管癌时实现可接受肺剂量的预测因素研究
Front Oncol. 2021 Oct 7;11:735062. doi: 10.3389/fonc.2021.735062. eCollection 2021.
多机构验证 RTOG 0617 入组患者基于知识的计划模型:对合作组试验中计划质量控制的影响。
Pract Radiat Oncol. 2019 Mar;9(2):e218-e227. doi: 10.1016/j.prro.2018.11.007. Epub 2018 Dec 15.
4
Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5 cm.基于知识的计划,用于确定大于 5cm 的肺肿瘤的高风险立体定向消融放射治疗计划。
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):259-267. doi: 10.1016/j.ijrobp.2018.08.013. Epub 2018 Aug 14.
5
Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies.立体定向放疗治疗肺部病变和常规放疗治疗原发性肺癌的淋巴结区域的可行性。
Radiat Oncol. 2018 Jul 11;13(1):127. doi: 10.1186/s13014-018-1071-5.
6
Risk factors for radiation pneumonitis after stereotactic radiation therapy for lung tumours: clinical usefulness of the planning target volume to total lung volume ratio.肺部肿瘤立体定向放射治疗后放射性肺炎的危险因素:计划靶体积与全肺体积比的临床应用价值
Br J Radiol. 2018 Jun;91(1086):20170453. doi: 10.1259/bjr.20170453. Epub 2018 Apr 16.
7
A novel IMRT planning study by using the fixed-jaw method in the treatment of peripheral lung cancer with mediastinal lymph node metastasis.一项关于使用固定准直器技术进行调强放射治疗计划的新研究,用于治疗伴有纵隔淋巴结转移的周围型肺癌。
Med Dosim. 2018;43(1):46-54. doi: 10.1016/j.meddos.2017.08.002. Epub 2017 Oct 27.
8
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.SBRT 推量同期放化疗治疗不可切除 III 期非小细胞肺癌:一项 I 期研究。
J Thorac Oncol. 2017 Nov;12(11):1687-1695. doi: 10.1016/j.jtho.2017.07.036. Epub 2017 Sep 13.
9
Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.局部晚期非小细胞肺癌同期放化疗后立体定向体部放疗增敏:1 期剂量递增研究。
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1021-1027. doi: 10.1016/j.ijrobp.2016.08.032. Epub 2016 Aug 31.
10
Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy.局部晚期非小细胞肺癌患者同步放化疗后局部和区域失败的差异分析。
Radiother Oncol. 2016 Mar;118(3):447-52. doi: 10.1016/j.radonc.2016.02.008. Epub 2016 Feb 15.